Rapid growth spurs McCann Health to recruit ex-Publicis HR exec as its first global chief talent officer

McCann Health hired Geline Midouin from digital agency  360i as global chief talent officer after 2016 rapid growth.

McCann Health has scooped Geline Midouin from digital agency 360i to serve as its first-ever global chief talent officer—a role she previously filled for more than five years at Publicis Healthcare.

Now, the McCann post marks a return to the healthcare industry for Midouin, a veteran human resources executive. McCann Health noted in an announcement that the new role was created after a year of rapid growth for the agency that included new business wins from GlaxoSmithKline, Bayer, Gilead and Janssen.

“I will be partnering with the leadership team to ensure that we attract and build high-performing teams that can drive innovation, collaboration and creativity,” Midouin said via email, adding that she’s also looking to create “transformational leaders.”


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

McCann Health Global CEO John Cahill in a statement praised Midouin for “her skills and depth of experience in human capital management, modern concepts in talent deployment and ways of working, and a rich appreciation of the value of a ‘people first’ approach that enables talent to do great work.”

Before Midouin joined Publicis, she spent 10 years at NBCUniversal in a variety of senior human resources roles, and worked as well at Arthur Andersen and Goldman Sachs.

The new global chief talent officer role at McCann Health follows another new executive post addition—chief growth officer for McCann Health North America—created in February.

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.